Davita Inc (DVA) Stock Price Today
Key Stats
- $15.03BMarket Cap
- -Volume
- HealthSector
- $236.9752W High
- $103.8752W Low
- -Typical Hold Time
- $27.58BEnterprise Value
- -Div Yield
- -Trading Activity
Track Davita Inc (DVA) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Davita Inc has traded between a low of $103.87 and a high of $236.97, highlighting its annual price range. Buy and sell Davita Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Most Recent News
City Holding Co director buys 110 shares amid 11.27% YTD stock gain and steady dividends.
A director of City Holding Co increased their stake by purchasing 110 shares at $134.55 each, signaling confidence in the company. The stock has risen 11.27% year-to-date and is trading near its 52-week high, reflecting strong market performance. Cit...
Global AI in drug repurposing market to hit $10.56B by 2035, growing at 23.4% CAGR
The global AI in drug repurposing market, valued at $1.28 billion in 2025, is projected to reach $10.56 billion by 2035 with a CAGR of 23.4%. This growth is driven by the need to accelerate drug discovery, reduce costs, and address chronic and rare d...
Stocks surge on acquisition news, speculative trading, and defense tech expansion
Stocks saw notable gains driven by specific events: Cynata Therapeutics surged over 800% due to speculative trading without known corporate news; Utz Brands jumped nearly 89% following a $14.25 per share acquisition offer now under shareholder fairne...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.